ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

At a General Meeting on 11 June 2025, shareholders approved the subdivision and redesignation of the Company’s Issued ...

Adstiladrin may now be thawed in a water bath following an FDA label update, facilitating more efficient treatment delivery for bladder cancer.

Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...

Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...

Accelerated water-bath thawing, completed in about 25 minutes, may help streamline clinical workflows and support efficient patient management -- Label update includes data showing that product ...

Federal health officials issued a warning Tuesday over misleading statements made by biotech billionaire Patrick Soon-Shiong, ...

ImmunityBio (IBRX) stock plummeted 21% after the FDA issued a warning letter citing false advertising claims about its ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC.

ImmunityBio (IBRX) stock falls as the FDA issues a warning letter regarding a TV commercial and a podcast related to the ...

En bloc resection of bladder tumor has recently emerged as an alternative to TURBT aiming to improve surgical quality and pathological assessment.